Table 3.

Hazard ratios for positive surgical margins predicting prostate cancer outcomes, stratified by pathological Gleason score, pathological stage, and PSA groups

	BCR			CRPC			Metastases			PC-specific mortality
	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
	Pathological Gleason score*
2–6	2.14	1.69–2.71	<0.001	1.42	0.43–4.75	0.568	1.18	0.56–2.49	0.669	1.81	0.45–7.25	0.401
7 (3+4)	1.92	1.59–2.34	<0.001	0.82	0.36–1.89	0.647	1.12	0.50–2.54	0.780	1.58	0.51–4.84	0.427
7 (4+3)	1.92	1.42–2.58	<0.001	1.26	0.40–3.97	0.694	1.13	0.40–3.19	0.815	0.70	0.20–2.50	0.582
8–10	1.99	1.47–2.69	<0.001	1.22	0.67–2.85	0.579	1.30	0.67–2.51	0.431	1.24	0.57–2.69	0.588
Pathological Stage**
T2	2.43	2.08–2.84	<0.001	1.65	0.83–3.28	0.151	1.69	0.95–3.01	0.074	2.05	0.83–5.06	0.121
T3/T4	1.28	1.06–1.55	0.010	0.90	0.52–1.54	0.693	0.99	0.61–1.63	0.981	1.08	0.59–1.97	0.803
PSA***
<4	2.39	1.40–4.10	0.001	0.32	0.02–4.83	0.408	1.26	0.30–5.33	0.752	N/A	-	-
4–9.9	1.98	1.69–2.33	<0.001	1.28	0.67–2.46	0.454	1.37	0.80–2.34	0.254	1.31	0.60–2.89	0.496
10–19.9	2.04	1.62–2.58	<0.001	1.01	0.47–2.15	0.985	1.01	0.50–2.03	0.978	1.04	0.96–1.10	0.931
!	2.22	1.43–3.44	<0.001	1.46	0.46–4.61	0.521	1.55	0.44–5.47	0.496	1.05	0.23–4.84	0.950

HR are vs. negative surgical margins

^*Adjusted for age, race, preoperative PSA, seminal vesicle invasion, extracapsular extension, year of surgery, surgical center, and receipt adjuvant therapy

^**Adjusted for age, race, preoperative PSA, pathological Gleason score, year of surgery, surgical center, and receipt adjuvant therapy

^***Adjusted for age, race, pathological Gleason score, seminal vesicle invasion, extracapsular extension, year of surgery, surgical center, and receipt adjuvant therapy

N/A indicates that model did not converge because of low event counts